Annovis Bio, Inc. (NYSE:ANVS) Financings

Annovis Bio, Inc.

Financings

RaiseDate
Public offering of shares of common stock (or pre-funded warrants) and accompanying warrants
Closed: US$21M raised · US$1 a share · Warrants at US$1 for 60 months · Canaccord Genuity
Dealers: Canaccord Genuity (lead)
Buyers: Chairman of the Board ($5.00 million, approximately 24% of the offering)
Insiders: The Chairman of the Board contributed $5.00 million, approximately 24% of the offering
Use of proceeds: Fund operations through the pivotal Phase 3 AD data readout and continued clinical development of buntanetap in AD and PD
Nov 9, 2026
Public offering of underwritten public offering
Closed: US$10M in the latest tranche · US$1.9 a share · Warrants at US$2.5 for 66 months · Canaccord Genuity
Dealers: Canaccord Genuity (lead)
Use of proceeds: Primarily to advance buntanetap through the pivotal Phase 3 Alzheimer's disease trial
Apr 13, 2026
Registered direct offering of shares of common stock
Announced: about US$3.4M · US$2.05 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Michael Hoffman; Dr. Maria Maccecchini
Insiders: Participation of Chairman Michael Hoffman and CEO Dr. Maria Maccecchini
Use of proceeds: Working capital and general corporate purposes
Oct 27, 2025
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof)
Closed: US$6M raised · US$1.5 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Oct 15, 2025

Read by 6ix AI from the company's releases